COMPANY PIPELINE

VACCINE PROGRAMS CURRENTLY UNDER DEVELOPMENT

CDIFFVAC: A novel broad-protective toxoid vaccine for prevention and treatment of Clostridium difficile infection

UTIVAC: A multi-faceted vaccine approach for prevention and treatment of urinary tract infection caused by UPEC

PTVAC: A more immunogenic and longer-lasting toxoid vaccine for prevention and treatment of whooping cough

CLOSTRIDIUM DIFFICILE INFECTION (CDI)

A significant unmet medical need

C. difficile is the leading cause of healthcare-associated infectious diarrhea
Disease symptoms caused by two toxins

CDI is mainly caused by antibiotic use
Patients >65 years are at higher risk
Recurrent infections in ca. 1 out of 4
Emerging AMR in C. difficile is a significant threat to global healthcare systems

> 800.000 infections
> 60.000 deaths

AMR Hazard level "Urgent Threats" (CDC)

CDI is associated with significant economic burden

5.9 billion EUR

in annual costs in the US due to CDI

2.8 billion EUR

in annual costs in the European Union due to CDI

CDI causes a wide spectrum of disease symptoms that are often debilitating

URINARY TRACT INFECTION (UTI)

One of the world's most common infections

Disease mainly caused by uropathogenic E. coli (UPEC) - ca. 80-90% of UTIs

Extensive use of antibiotic has caused a huge emerging AMR problem
- 10-20% of UPEC strains are multi drug resistant
Recurrent infections in ca. 1 out of 3

> 400 million infections
> 236.000 deaths

60% of women have ≥ 1 UTI per lifetime
11% of women have ≥ 1 UTI per year

WHOOPING COUGH

Resurging due to waning vaccine protection

Whooping cough is a contagious respiratory tract infection
The infection is caused by Bordetella pertussis which secretes pertussis toxin

Current vaccines show waning effectiveness a few years after booster shots

> 24 million infections
> 160.000 deaths

Macrolide-resistant B. pertussis is on CDC's AMR "Watch List"

FOLLOW OUR PROJECTS

rj@proxibiotech.com